Pharsight

Ozurdex patents expiration

OZURDEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702539 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(8 months ago)

US8034366 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(8 months ago)

US8034370 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(8 months ago)

US8506987 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(8 months ago)

US9192511 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(8 months ago)

US10076526 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(8 months ago)

US6899717 ALLERGAN Methods and apparatus for delivery of ocular implants
Nov, 2023

(a month from now)

Ozurdex is owned by Allergan.

Ozurdex contains Dexamethasone.

Ozurdex has a total of 7 drug patents out of which 6 drug patents have expired.

Expired drug patents of Ozurdex are:

  • US10702539
  • US8034366
  • US8034370
  • US8506987
  • US9192511
  • US10076526

Ozurdex was authorised for market use on 17 June, 2009.

Ozurdex is available in implant;intravitreal dosage forms.

Ozurdex can be used as delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex, treatment of diabetic macular edema; treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); treatment of non-infectious uveitis affecting the posterior segment of the eye, treatment of macular edema; treatment of uveitis.

The generics of Ozurdex are possible to be released after 01 November, 2023.

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 17 June, 2009

Treatment: Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); Treatment of non-infectious uveitis affecting t...

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

OZURDEX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic